Chemically Engineered NK Cells for Cancer Immunotherapy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F24%3A00602640" target="_blank" >RIV/61388963:_____/24:00602640 - isvavai.cz</a>

Alternative codes found

RIV/61388963:_____/24:00602646

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Chemically Engineered NK Cells for Cancer Immunotherapy

Original language description

The approval of chimeric antigen receptor (CAR) T cell therapies fueled the interest in the use of genetically modified immune cells in cancer therapy. Despite the enthusiasm generated especially in hemato-oncology, there are still many challenges associated with the widespread use of CAR technology. The major obstacles include the inefficient and time-consuming production associated with high costs, inefficiency in solid tumors and safety issues associated with the use of viral transduction systems. All of these and the recently initiated FDA investigations on the increased risk of T cell cancers in patients treated with CAR T products raises the need for the development of alternative approaches to their production. Such approaches enabling the production of re-engineered immune cells faster, safer and at lower price could make the adoptive cell transfer therapy accessible to a larger number of patients. The presented technology employs modified metabolic precursors, which are processed by cellular metabolic pathways to fabricate living cells containing an unnatural chemical functional group on the cell surface. This unnatural chemical groups can be subsequently used for the covalent attachment of different functional groups to cell surfaces using biocompatible chemical reaction. In this way, the methodology enables re-engineering of immune cells (e.g. NK cells) with targeting moieties that include small molecule binders, peptides, oligonucleotides, proteins, enzymes or therapeutic antibodies. These modified immune cells are more efficient in killing cancer than unmodified cells.

Czech name

—

Czech description

—

Type

O - Miscellaneous

CEP classification

—

OECD FORD branch

30102 - Immunology

Project

<a href="/en/project/TN02000109" target="_blank" >TN02000109: Personalised Medicine: From Translational Research into Biomedical Applications</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů